Krogsgaard: Lilly could pave the way for Novo
Novo Nordisk’s chief researcher welcomes the arrival of Eli Lilly as a worthy rival on a market that has so far been dominated by the Danish company’s drug Victoza. The rival could lead the way for Novo, he says.
by Stefan Singh Kailay
Last week, Eli Lilly became the first company to give Novo’s Victoza a run for its money, but the chief scientific officer of the Danish diabetes group, Mads Krogsgaard Thomsen, is not fazed by the development, quite to the contrary.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Victory for Novo-rival
For abonnenter
Novo: It feels like a big deal
For abonnenter
